Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Exai Bio
AddedFeb 15, 2024
UpdatedJun 18, 2026
Exai Bio

Exai Bio

Series A

Exai Bio: A next-gen company specializing in AI-based liquid biopsy and Orphan non-coding RNAs.

HQ
Palo Alto, CA, US
Founded
2021
Overview
Compare
Fundraising
Employees
Website

Exai Bio, founded with a mission to revolutionize cancer diagnostics and treatment, focuses on early and accurate detection of cancer through its next-generation RNA-based platform. Utilizing AI and orphan non-coding RNAs, Exai Bio offers liquid biopsy services that provide actionable insights into cancer biology from a simple blood draw. The company aims to transform how cancer is diagnosed, treated, and managed, making significant strides in the field of oncology.

Notable figures affiliated with Exai Bio include leading scientists and industry experts in oncology and biotechnology. The company has garnered attention from prominent investors in the biotech sector, contributing to its rapid growth and development. Key achievements include breakthroughs in their novel oncRNA technology, which have positioned Exai Bio as a pioneer in AI-driven liquid biopsies. The overall impact of Exai Bio is significant, offering hope for earlier cancer detection and improved patient outcomes.

Exai Bio - Similar Companies

Salish Bioscience logo

Salish Bioscience

Earli logo

Earli

earli.com

Liquid Biotech logo

Liquid Biotech

Lucence logo

Lucence

lucence.com

AccuraGen logo

AccuraGen

BioAI Health logo

BioAI Health

bioaihealth.com

Circulogene Theranostics logo

Circulogene Theranostics

circulogene.com

NonExomics logo

NonExomics

nonexomics.com

Nexosome Oncology logo

Nexosome Oncology

Droplet Biosciences logo

Droplet Biosciences

dropletbiosci.com

Oncodea logo

Oncodea

oncodea.com

Micronoma logo

Micronoma

micronoma.com

OncXerna Therapeutics logo

OncXerna Therapeutics

oncxerna.com

Mercy BioAnalytics logo

Mercy BioAnalytics

mercybio.com

Apostle logo

Apostle

apostlebio.com

Exai Bio - Quick Facts

Who are Exai Bio's competitors?

Companies similar to Exai Bio include Salish Bioscience, Earli, Liquid Biotech and Lucence.

When was Exai Bio founded?

Exai Bio was founded in 2021.

Where is Exai Bio's headquarters located?

Exai Bio's headquarters is located in Palo Alto, CA, US.

When was Exai Bio's last funding round?

Exai Bio's most recent funding round was for $67.5M (USD) in December 2021.

How much has Exai Bio raised to-date?

As of Dec 9, 2021, Exai Bio has raised a total of $67.5M (USD).

How many employees does Exai Bio have?

Exai Bio has 72 employees as of Feb 5, 2024.

Exai Bio - Classification

Ownership
  • Venture Capital
Technology
  • AI
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Liquid Biopsy
Tags
  • Data Information
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 12 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified